Companies Dominating the Gluten Intolerance Treatment Landscape
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- ActoBio Therapeutics, Inc.
- Precigen, Inc.
- Calypso Biotech BV
- ImmunogenX, Inc.
- Alvine Pharmaceuticals
- Dr. Falk Pharma GmbH
- ImmusanT, Inc.
- Zedira GmbH
- FunZyme BioTechnologies S.A.
- Amyra Biotech AG
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of gluten intolerance treatment is assessed at USD 1.03 billion.
The gluten intolerance treatment market size was over USD 842.52 million in 2024 and is projected to reach USD 4.52 billion by 2037, witnessing around 13.8% CAGR during the forecast period i.e., between 2025-2037. The growing prevalence of autoimmune, allergic, and non-autoimmune-allergic GRDs and the rising damage of gut flora will boost the market growth.
Europe industry is predicted to dominate majority revenue share of 34% by 2037, due to increasing review of the broad spectrum of gluten-related disorders, with focused clinical investigations, diagnostic criteria, and therapeutic approaches for different conditions causing gluten intolerance.
The major players in the market are Takeda Pharmaceutical Company Limited, ActoBio Therapeutics, Inc., Precigen, Inc., Calypso Biotech BV, ImmunogenX, Inc., Alvine Pharmaceuticals, Dr. Falk Pharma GmbH, ImmusanT, Inc., Zedira GmbH, FunZyme BioTechnologies S.A., Amyra Biotech AG
